NCT06730009 - Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 21, 2024

Primary Completion Date

January 31, 2029

Study Completion Date

August 31, 2029

Conditions

Pancreatic Carcinoma Stage IICholangiocarcinoma Resectable

Interventions

BIOLOGICAL

SLOG + Allogeneic NK cell

"Drug: SLOG chemotherapy S-1, leucovorin, oxaliplatin, and gemcitabine (SLOG)~Biological:~Allogeneic Magicell-NK contains NK cells suspended in 100 mL of normal saline Ph I dose starts at 10 × 10\^8 cells (Cohort 1) and escalates to 20 × 10\^8 cells (Cohort 2).~Ph II dose will be determined lower than or equal to Ph I MTD/MFD."

DRUG

SLOG chemotherapy

Drug: SLOG chemotherapy S-1, leucovorin, oxaliplatin, and gemcitabine (SLOG)

Trial Locations (1)

138

RECRUITING

National Cheng Kung University Hospital, Tainan City